Abstract Multiform glioblastoma (GBM) is the most aggressive primary brain tumor, associated with high heterogeneity, treatment resistance, and poor survival. Temozolomide (TMZ), although the main chemotherapeutic agent used, shows limited efficacy due to low solubility, chemical instability, and acquired resistance. In this context, nanostructured systems can enhance their antitumor efficacy. This study aimed to develop and characterize chitosan-functionalized nanostructured lipid carriers loaded with Temozolomide (NLCTQ), as well as to assess their biological activity in human glioblastoma cells (U87-MG). Lipid nanoparticles functionalized with chitosan were prepared by hot emulsification and sonication. Physicochemical characterization included DLS, zeta potential, FTIR, and HPLC for drug quantification and encapsulation efficiency. Biological activity was evaluated in U87-MG cells using the cell viability assay MTT and trypan blue, the comet assay, the spheroid model, fluorescence cell death, and the CBMN assay. The formulation presented a homogeneous nanometric size and positive zeta potential, although with moderate encapsulation efficiency (39%). Biological assays demonstrated that NLCTQ significantly reduced cell viability, overcoming the U87-MG cell line’s resistance to TMZ by achieving cytotoxicity at doses up to 20 times lower than free TMZ. Additionally, NLCTQ promoted the formation of biomarkers of chromosomal instability, such as micronuclei, bridges, and nuclear buds, which may explain the observed cytotoxic effects. Together, the results indicate that TMZ nanoencapsulation in NLCTQ enhances its antitumor efficacy, representing a promising strategy to overcome the limitations of conventional chemotherapy in glioblastoma treatment.
Negreiros et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: